Definition and Mechanism of Trispecific Antibodies

Trispecific antibodies are next-generation biopharmaceuticals that bind to three target proteins simultaneously, maximizing therapeutic efficacy. They overcome the limitations of conventional bispecific antibodies and offer advantages in complex disease areas such as cancer and autoimmune diseases by preventing the development of resistance. Development is focused on T-cell engagers, which bind to the CD3 receptor and two antigens on the surface of cancer cells. Recently, the market has expanded beyond solid tumors to include various immune-related diseases, attracting significant attention.

Clinical Trial Results and Expansion of Indications by Global Big Pharma Companies

Global pharmaceutical companies are accelerating preclinical trials to validate the commercial potential of trispecific antibodies. Pfizer achieved an EASI-75 score of over 75% in its Phase 2 clinical trial of Tilrekmig, which targets IL-4, IL-13, and TSLP simultaneously for the treatment of atopic dermatitis, and is preparing to initiate a Phase 3 trial within the year. Johnson & Johnson also demonstrated improved safety profiles in its Phase 1 clinical trial of JNJ-79635322 for multiple myeloma patients, achieving an objective response rate (ORR) of 86.1%. These clinical successes can significantly contribute to addressing the unmet needs of complex and refractory diseases.

Market Restructuring by Big Pharma through Multi-Billion Dollar Technology Acquisitions

The high commercial potential of trispecific antibodies is evident in the multi-billion dollar licensing agreements. Sanofi acquired KT501, a target for autoimmune diseases, from Kali Therapeutics for a total of $1.23 billion, including an upfront payment of $180 million and milestone payments of $1.05 billion. AbbVie also acquired the global rights to ISB 2001, a treatment for multiple myeloma, from Ichnos Glenmark Innovation for a total of $1.925 billion, including an upfront payment of $700 million and milestone payments of $1.225 billion. Excalipoint Therapeutics also licensed EXP011 and other products from Lepu Biopharma for a total of $857.5 million, aiming to gain a foothold in the small cell lung cancer (SCLC) market.

Technical Challenges and Prospects for Commercialization

Despite their unique efficacy, trispecific antibodies pose challenges in commercialization due to their complex molecular structure, including ensuring production stability and controlling immune-related adverse effects. Companies with advanced engineering platforms that can stably express proteins without interference between the three binding sites are likely to gain a leading position in the market. Efforts are also underway to optimize the dosage to minimize adverse effects such as cytokine release syndrome (CRS) associated with T-cell activation. The industry expects the first trispecific antibody drug to be approved around 2028, based on the accumulation of clinical data and innovation in manufacturing processes, and anticipates high growth in the next-generation immunotherapy market.